SensoDetect

To help address specific medical issues, write, and review educational materials, establish research funding, identify fundraising opportunities and act as an ambassador for the SensoDetect's method, the company has appointed a prominent expert Medical Doctor within the field of Autism as the chairman of the SensoDetect medical advisory board. The name of the MD will be announced by SensoDetect together with Arabian Trade House in conjunction with the opening ceremony of the Autism study “Early, objective detection of autism” at the Princess Noura University Hospital, Riyadh, Saudi Arabia, during January in 2024. 

“We have an ambitious healthcare program included in the Saudi Vision 2030. A part of this is ensuring comprehensive, effective, and integrated health care with data-driven treatment plans. We are also prioritizing innovation in the areas of e-health services and digital solutions to continuously improve the quality and access to healthcare. In all these respects the SensoDetects method qualify. Furthermore, the solutions provided by SensoDetect is in line with Saudi Arabia’s continued investments in mental health infrastructure, including building specialized centers and clinics, increasing the number of mental health professionals, and raising awareness about mental health through campaigns and educational initiatives. In summary we are working hard to ensure the Kingdom’s national health goal, to ensure everyone has access to high-quality healthcare. The initiative together with SensoDetect is one of them.” Says the consulting VP of sales at the Medical department of Arabian Trade House.   

“With such a prominent and influential MD as our advisor and ambassador, our outreach across the entire region gains momentum. With his authority and expertise, the study approved and with the strong support of our distributor Arabian Trade House, we have now paved the way for SensoDetect's expansion across the entire GCC. We will start by focusing on Saudi Arabia and UAE where we see a potential market of up to SEK 2 billion only for SensoDetect Diagnostics. When considering SensoDetect Medication and SensoDetect Health within the whole of GCC, the potential increases significantly. To effectively tap into the GCC market, we are now making a new emission of shares to have the financial and organizational resources needed to deliver on our large potential. This is a big moment for SensoDetect and so I am very much looking forward to personally attend the opening ceremony in January 2024 and to continue to deliver success in the GCC region in the years to come.” says CEO Per-Anders (PA) Hedin.